First-generation epithelial growth factor receptor tyrosine kinase inhibitor in the first-line treatment of advanced non-small cell lung cancer: 166 cases analysis of progression-free survival / 中国实用内科杂志
Chinese Journal of Practical Internal Medicine
;
(12): 460-463, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-816046
ABSTRACT
OBJECTIVE:
Explore the clinical benefit factors of progression-free survival(PFS) in sensitive epithelial growth factor receptor(EGFR) gene mutated advanced non-small cell lung cancer patients treated with first-generation of EGFR tyrosine kinase inhibitor(TKI).METHODS:
The clinical data of 166 patients who received first-line treatment with first-generation EGFR-TKI were retrospectively collected in 2016-2017 from Xiangya Hospital, Central South University. The patients were divided into three groups PFS≤3 m,3 mCONCLUSION:
NSCLC patients with EGFR sensitive mutation may have different PFS at different baseline states such as histological type, differentiation degree, EGFR gene mutation type. First-generation EGFR-TKI may be an independent factor affecting PFS.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Practical Internal Medicine
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS